How do pediatric psychiatry nurses explain SSRI prescriptions for adolescent depression to Spanish-speaking parents who are afraid of the FDA black box warning about antidepressants and suicidal thinking?

The SSRI-for-adolescent-depression conversation is one of the most common and most misunderstood in pediatric psychiatry, because the FDA black box warning added to all antidepressants in 2004 was widely reported in media as 'antidepressants cause suicide in teenagers,' which is not what the warning says and is not what the clinical evidence shows. The nurse's first task is to clarify exactly what the warning states and why, and then to provide the accurate epidemiological framing. What the FDA black box warning says: a reanalysis of 24 clinical trials of antidepressants in children and adolescents found a small but statistically significant increase in suicidal ideation — reports of thoughts of suicide or self-harm — in the first weeks of treatment compared to placebo (4% vs 2% of participants); no completed suicides occurred in any of the 4,400 participants across the trials; the warning does not say antidepressants cause completed suicide. What causes the increased suicidal ideation reports: the proposed mechanism is activation syndrome — a cluster of symptoms including increased energy, agitation, impulsivity, irritability, and insomnia that occurs in a subset of patients in the first four to eight weeks of SSRI treatment as serotonergic circuits begin responding to the drug before the full antidepressant mood effect develops; this activation can transiently increase the vividness, urgency, or actionability of pre-existing suicidal thoughts in patients who already have passive suicidal ideation as part of their depression; it is not a new insertion of suicidal ideation in patients who had none — it is an amplification of what was already present during a narrow transition period. The management: close monitoring in the first four to eight weeks — the FDA and American Academy of Child and Adolescent Psychiatry recommend weekly contact during this period; patients and families are given specific warning signs (increase in agitation, new or increased talk of suicide, self-harm behavior) and a clear escalation pathway. The epidemiological context: US adolescent suicide rates declined substantially from the mid-1990s through the early 2000s as SSRI prescribing increased following the approval of fluoxetine for pediatric depression; suicide rates in adolescents rose again after 2004 as SSRI prescribing to adolescents declined following the black box warning and media coverage; the population-level data associate increased SSRI prescribing with reduced adolescent suicide. The risk of untreated moderate-to-severe adolescent depression: major depressive disorder in adolescence with passive suicidal ideation, functional impairment, and seven weeks of sustained symptoms carries elevated risk of suicide attempt; first episode in adolescence is associated with recurrence in adulthood in 40 to 70 percent of cases; leaving moderate-to-severe adolescent depression untreated is not a neutral or safer option. For the Spanish-speaking parent: 'La advertencia de la FDA no dice que los antidepresivos causan suicidio. Dice que en las primeras semanas de tratamiento, en algunos adolescentes, puede haber un aumento temporal en los pensamientos de hacerse daño — no en el suicidio completado, sino en los pensamientos. Eso ocurre porque el medicamento empieza a dar energía antes de que el estado de ánimo mejore. Por eso el protocolo es vigilancia cercana en las primeras semanas — citas semanales, llamadas si hay algún cambio. Y la otra parte que importa: sin tratamiento, la depresión de Valentina tiene un riesgo más alto de suicidio que con tratamiento y vigilancia. Los estudios de la población muestran que los adolescentes que no reciben tratamiento para la depresión tienen más intentos de suicidio, no menos. La advertencia en la caja es real. El plan de vigilancia es la respuesta a esa advertencia. No es razón para dejar la depresión sin tratar.'

How do pediatric psychiatry nurses explain exposure and response prevention therapy for OCD to Spanish-speaking parents who cannot understand why the treatment deliberately makes their child more anxious when the goal is reducing anxiety?

The ERP conversation is one of the most counterintuitive in all of pediatric psychiatry because the therapy's immediate visible effect — a distressed child sitting with his contaminated hands in his lap, unable to wash, his anxiety visibly elevated — looks to the parent like cruelty or therapeutic error rather than evidence that treatment is working. The nurse must explain two things: why OCD is self-sustaining without ERP, and why inducing anxiety and preventing the compulsion is the mechanism of cure rather than a means to an end. Why OCD is self-sustaining: OCD is maintained through operant conditioning of the anxiety-compulsion-relief cycle. The obsessive thought (I have touched a contaminated surface) generates anxiety. The compulsion (washing) generates immediate, reliable relief. The immediate relief negatively reinforces the compulsion — the brain records that washing terminated the anxiety, washing is necessary to terminate anxiety, and the compulsion must be repeated whenever the obsession occurs. With each repetition, two things happen: the relief from washing becomes more necessary (the brain has more evidence that washing is required), and the anxiety threshold for triggering a compulsion decreases (increasingly minor contamination triggers the full cycle). Left untreated, OCD escalates. Why ERP works: ERP interrupts the compulsion-reinforcement cycle by introducing a new learning trial in which the obsession occurs, anxiety rises, and the compulsion does not follow. What happens when the compulsion is withheld and the patient stays with the anxiety: the anxiety rises to its peak — this is the distressing visible phase — and then, through the neurobiological habituation response, it decreases on its own without the compulsion. The amygdala's threat-response circuit habituates when the anticipated catastrophic consequence (severe illness from the contamination) does not materialize; the anxiety signal decreases because the threat prediction is repeatedly disconfirmed. Two specific things the brain learns through repeated ERP trials: first, anxiety decreases without the compulsion (the compulsion is not necessary to end the anxiety — time and habituation end it); second, the feared catastrophic consequence does not occur (touching the doorknob does not cause severe illness — the obsessional belief is empirically disconfirmed by experience). After enough trials, the conditioned link between the obsession and the anxiety weakens because the brain's prediction model is corrected. The treatment efficacy: SSRI monotherapy achieves 40 to 50 percent response in pediatric OCD by moderating the serotonergic tone that amplifies the anxiety-compulsion cycle; ERP achieves 65 to 70 percent response by directly modifying the learned association; combined treatment achieves the highest response rates. For the Spanish-speaking parent: 'El OCD de Miguel se mantiene porque lavar le da alivio inmediato. El cerebro aprende que lavar es lo que para la ansiedad. Cada vez que lava, confirma esa lección. La terapia hace algo diferente: le enseña al cerebro que la ansiedad baja sola, sin lavar. Para enseñarle eso, Miguel tiene que sentir la ansiedad sin lavar — y quedarse con ella hasta que su cerebro compruebe que baja sola y que el desastre que teme no ocurre. La ansiedad que usted vio en la sesión es la terapia trabajando, no un error. El momento en que la ansiedad bajó sin que Miguel lavara — ese es el momento en que el cerebro aprende. Cada vez que eso pasa, la conexión entre tocar algo y sentir esa ansiedad es un poco más débil.'

How do pediatric psychiatry nurses explain antipsychotic treatment for cannabis-precipitated first episode psychosis to Spanish-speaking parents who believe stopping cannabis should resolve the psychosis?

The cannabis-precipitated psychosis conversation requires the nurse to explain a distinction that is not intuitive even to medically educated parents: the difference between a pharmacological toxidrome (a state caused by and sustained by an active drug) and a drug-precipitated disorder (a state triggered by a drug but then sustained by an independent neurobiological mechanism). The parent's model — cannabis caused the psychosis, therefore stopping cannabis resolves the psychosis — is accurate for cannabis intoxication psychosis but wrong for cannabis-precipitated first episode psychosis, and the clinical evidence that distinguishes them is the timeline. Cannabis intoxication psychosis: acute psychotic symptoms (paranoia, perceptual distortions, disorganized thinking) can occur during high-THC-concentration cannabis exposure, particularly in individuals with no prior use or with high-potency preparations; these symptoms are pharmacologically maintained by ongoing THC activity at CB1 receptors in the prefrontal cortex and mesolimbic system; they resolve within hours of drug clearance as THC is metabolized; they constitute a pure toxidrome. Cannabis-precipitated first episode psychosis: the psychotic symptoms persist days to weeks after verified cannabis cessation, establishing that the psychosis is not pharmacologically maintained; the mechanism requires understanding how THC disrupts adolescent brain maturation in genetically vulnerable individuals; the adolescent brain undergoes extensive synaptic pruning and maturational refinement of mesocortical dopamine circuits between ages 12 and 25 — this process is activity-dependent and guided by endocannabinoid signaling at CB1 receptors in the prefrontal cortex; THC partially agonizes these CB1 receptors during the critical maturational window, disrupting the pruning process; in individuals with genetic predisposition to schizophrenia-spectrum disorders (which affects 1 to 3 percent of the population and is identifiable by family history of psychosis, schizotypy traits, or minor neurological soft signs), this disruption triggers the mesolimbic dopamine dysregulation cascade — elevated dopamine synthesis and release in the striatum, increased D2 receptor sensitivity — that underlies the positive symptoms of psychosis; critically, this cascade, once initiated, acquires a self-sustaining neurochemical mechanism independent of THC; the endocannabinoid disruption was the trigger, not the ongoing cause; follow-up studies including large Danish registry studies and the AESOP first episode study show 35 to 50 percent of cannabis-associated first episode psychosis cases develop DSM-defined schizophrenia or schizoaffective disorder at 3 to 5 year follow-up even with complete cannabis abstinence; early antipsychotic treatment (within weeks of first episode) is associated with better functional outcomes at 2 and 5 years compared to delayed treatment; risperidone at 1 to 2 mg in an adolescent blocks dopamine D2 receptors in the mesolimbic pathway, normalizing the excess dopamine signaling driving the hallucinations and delusions — this is the treatment mechanism; the side effects (weight gain, sedation, metabolic effects) are real and monitored but are manageable and reversible, unlike untreated psychosis. For the Spanish-speaking parent: 'La diferencia entre una intoxicación por marihuana y lo que tiene Andrés es el tiempo. Una intoxicación se va cuando el cuerpo elimina la droga — horas, máximo un día. Andrés lleva cuatro semanas y tres días sin marihuana y las alucinaciones y los miedos siguen ahí. Eso nos dice que la marihuana ya no está causando los síntomas — los desencadenó, pero ahora el cerebro los está produciendo solo. La marihuana encendió algo en la química del cerebro de Andrés que ahora funciona de manera independiente. El antipsicótico normaliza esa química. Sin él, los síntomas continúan independientemente de la marihuana.'

What are the key clinical Spanish phrases for explaining psychiatric medications, OCD therapy, and psychosis treatment to Spanish-speaking families in pediatric psychiatry clinic?

Pediatric psychiatry clinic nurses need clinical Spanish for three distinct categories: SSRI treatment for adolescent depression, OCD and ERP therapy, and first episode psychosis treatment. For SSRI treatment and the FDA black box warning — explaining the warning accurately: 'La advertencia en la caja de los antidepresivos no dice que el medicamento causa suicidio. Dice que en las primeras semanas puede haber un aumento en los pensamientos de hacerse daño — no en el suicidio completado. Eso ocurre en una minoría de pacientes y es por eso que el protocolo es vigilancia semanal al principio.' For explaining activation syndrome: 'Al inicio del tratamiento, en algunas personas, el medicamento da más energía antes de que el estado de ánimo mejore. Si su hija/hijo ya tenía algunos pensamientos de hacerse daño, ese período de más energía puede hacer esos pensamientos más vividos temporalmente. Por eso llamamos cada semana en las primeras semanas. Queremos saber si la energía sube antes de que el ánimo suba.' For explaining the risk comparison: 'La depresión de su hija/hijo sin tratar tiene un riesgo más alto de suicidio que la depresión tratada con medicamento y vigilancia cercana. Los estudios muestran eso de manera consistente. La advertencia es real y la tomamos en serio — por eso el plan de vigilancia. Pero no tratar también tiene un riesgo.' For OCD and ERP — explaining the maintenance cycle: 'El OCD se mantiene porque el ritual da alivio. Cada vez que su hijo/a hace el ritual, el cerebro confirma que el ritual es necesario para que la ansiedad pare. Con el tiempo el ritual tiene que ser más largo, más frecuente, y cualquier cosa pequeña lo dispara.' For explaining ERP: 'La terapia de exposición y prevención de respuesta interrumpe ese ciclo. Expone a su hijo/a a lo que teme, y le impide hacer el ritual. La ansiedad sube — eso es lo que usted va a ver. Pero si no hace el ritual, la ansiedad baja sola. El cerebro aprende dos cosas: que puede aguantar la ansiedad sin el ritual, y que el desastre que teme no ocurre.' For explaining the habituation mechanism: 'La habituación es lo que hace que la ansiedad baje sola. Es una respuesta biológica del cerebro — cuando la amenaza que teme no ocurre, el cerebro reduce la señal de alarma. Cada sesión de exposición exitosa hace esa señal un poco más débil para ese estímulo específico.' For first episode psychosis — explaining intoxication vs. precipitation: 'Hay una diferencia importante entre una psicosis por intoxicación — que se va cuando el cuerpo elimina la droga — y una psicosis precipitada por una droga — que sigue después. Si fuera intoxicación, habría pasado en el primer día. Lleva semanas. Eso indica que ya no depende de la droga.' For explaining dopamine dysregulation: 'La marihuana en la adolescencia puede afectar la manera en que el cerebro maneja la dopamina. En algunas personas con predisposición genética, ese efecto no se revierte cuando se para la droga — el cerebro queda con un nivel de dopamina demasiado alto en ciertas áreas, y ese nivel alto produce las voces y los miedos. El antipsicótico normaliza ese nivel.' For explaining antipsychotic side effects: 'El medicamento puede causar aumento de peso y somnolencia, especialmente al principio. Eso lo vigilamos con análisis de sangre cada tres meses. Si el aumento de peso es significativo, tenemos opciones para manejarlo. Los efectos secundarios son manejables y reversibles. Los síntomas psicóticos sin tratamiento no son ninguna de esas cosas.'

Why does the FDA black box warning on antidepressants not mean SSRIs should be avoided in adolescents with major depression, and how do nurses explain the risk-benefit balance to Spanish-speaking parents?

The FDA black box warning on antidepressants and suicidality was added in 2004 after a meta-analysis of 24 pediatric clinical trials found a small but statistically significant increase in suicidal ideation (thoughts, not acts) in the treatment groups compared to placebo — approximately 4 percent versus 2 percent of participants reported suicidal ideation. No completed suicides occurred across the approximately 4,400 trial participants. The interpretation problem arises because 'black box warning' signals the highest level of FDA safety concern, and 'suicidal' in public communication is often collapsed to 'suicide completion,' creating the impression that antidepressants cause adolescent suicide deaths. The clinical picture is more nuanced. The mechanism of the increased ideation reports: the leading explanation involves activation syndrome — increased serotonergic tone in the early weeks of treatment generates energy, agitation, and impulsivity before the antidepressant mood effect develops fully; in a patient with pre-existing passive suicidal ideation (thoughts of death or wishing to be dead without plan or intent, which are part of the diagnostic criteria for major depression), this activation can transiently increase the intensity or urgency of those thoughts; the key phrase is 'pre-existing' — the ideation was present before treatment, part of the depression, and activation syndrome amplified it temporarily during titration rather than inserting it de novo; patients without pre-existing suicidal ideation do not show the same risk. The epidemiological context: the SSRI era (1990s–early 2000s) was associated with substantial declines in US adolescent suicide rates; the period following the black box warning (2004–2008) was associated with declines in adolescent SSRI prescribing and subsequent increases in adolescent suicide rates; while causation cannot be definitively established from ecological data alone, the direction is inconsistent with the 'SSRIs cause suicide' narrative and consistent with 'undertreated adolescent depression is associated with completed suicide.' The risk-benefit analysis for moderate-to-severe adolescent major depression: major depressive disorder in adolescence with sustained symptoms (seven or more weeks), significant functional impairment, and passive suicidal ideation is not a benign condition that resolves spontaneously — it carries risk of suicide attempt, risk of recurrence in adulthood (40 to 70 percent have a second episode), risk of academic and social developmental disruption, and risk of progressing to bipolar disorder in a subset; the TADS trial, the largest randomized controlled trial of adolescent depression treatment, found that fluoxetine plus CBT produced a 71 percent response rate at 12 weeks, fluoxetine alone 61 percent, CBT alone 43 percent, and placebo 35 percent; serious suicidal events occurred across all treatment arms including placebo, at similar rates; the management of the black box risk is clinical monitoring, not treatment avoidance. For the Spanish-speaking parent: 'La advertencia de la FDA es sobre un riesgo real que existe en las primeras semanas y que requiere vigilancia. No es un argumento para no tratar la depresión — es un argumento para tratar con vigilancia. El protocolo que le estoy explicando — citas semanales, usted me llama si ve estos cambios específicos, volvemos en siete días — es exactamente la respuesta clínica correcta a esa advertencia. Lo que no es correcto es decir que la advertencia significa que su hija no debe recibir tratamiento. La depresión sin tratar también tiene un riesgo. Estamos eligiendo el camino con más protecciones, no el camino sin riesgo, porque ese camino no existe.'

Spanish for pediatric psychiatry clinic nurses — the father who cannot understand why his depressed teenager is prescribed an SSRI when he heard antidepressants cause suicidal thinking in teenagers not knowing the FDA black box warning refers to activation-syndrome suicidal ideation in the first weeks of titration and untreated adolescent depression carries substantially higher lifetime suicide risk than treated depression under close monitoring, the mother who cannot understand why her son with OCD is deliberately made more anxious in therapy when the goal is to reduce anxiety not knowing exposure and response prevention works through habituation that extinguishes the conditioned anxiety–compulsion link when the compulsion is withheld during the anxiety peak, and the mother who cannot understand why her daughter’s cannabis-triggered psychosis is treated with an antipsychotic that causes weight gain when stopping cannabis should resolve the psychosis not knowing cannabis-precipitated first episode psychosis in genetically vulnerable adolescents is not a pharmacological toxidrome but a drug-precipitated autonomous expression of underlying psychotic vulnerability

The pediatric psychiatry clinic nurse’s communication challenge

Psychiatric diagnoses and treatments carry a specific communication burden that most other medical specialties do not: they engage cultural beliefs about mental illness, family shame and stigma, fear of medication effects on the developing brain, and — in Spanish-speaking families with limited access to mental health information in their language — often a foundational model of mental health disorders as spiritual or moral failures rather than medical conditions with neurobiological mechanisms. A pediatric psychiatry clinic nurse working with Spanish-speaking families must first validate the family’s presence and concern, then build the biological framework from scratch, before the treatment instruction means anything.

Three conversations from a pediatric psychiatry clinic illustrate three distinct communication failures that are among the most common in this specialty: the parent who has read a true fact (the FDA black box warning is real) but has drawn the wrong clinical conclusion from it; the parent who watches a therapy session and correctly describes what they saw (the child was anxious) but does not understand the mechanism that makes that anxiety the therapeutic agent; and the parent whose causal model is accurate for one diagnosis (cannabis intoxication) but not for the diagnosis in front of them (cannabis-precipitated first episode psychosis).

In each case, the gap is mechanistic. Closing it requires the nurse to explain activation syndrome and epidemiological context, the neurobiology of habituation and the operant conditioning of the compulsion cycle, and the distinction between a pharmacological toxidrome and a drug-precipitated autonomous disorder. These are not simple concepts. They are the actual mechanism of the conditions and the treatments, and without them the treatment instruction is just an instruction, fragile against the first internet search, the first family member’s objection, or the first week of side effects.

Scenario 1: Valentina García-Reyes — 16 years old, Houston, Texas

Valentina García-Reyes had been referred to the pediatric psychiatry clinic by her school counselor after a teacher flagged declining grades, withdrawal from her friend group, and a comment Valentina made about “not seeing the point anymore.” The evaluation confirmed a moderate-to-severe major depressive episode: nine of nine DSM-5 criteria met, sustained for seven weeks, with significant functional impairment, social withdrawal, early morning awakening, loss of interest in activities she had previously loved, and passive suicidal ideation — thoughts of death and wishing to be dead, without a specific plan. The child psychiatrist prescribed sertraline 50 mg daily for the first two weeks, titrating to 100 mg, with weekly monitoring contact during the first eight weeks.

Valentina’s father Ernesto García-Torres, a security guard who worked night shifts, had done his research. He had found three articles and a news segment from 2004 about the FDA requiring a black box warning on antidepressants because they caused suicidal thinking in teenagers. He had also found a parent forum where several families described their children becoming more agitated and making a first attempt while on antidepressants. He had come to the follow-up appointment at the pediatric psychiatry clinic with specific concerns.

“Necesito entender algo antes de darle a Valentina este medicamento,” he said to pediatric psychiatry clinic nurse Ana Morales-Espinoza. “La FDA puso una advertencia especial en la caja de los antidepresivos diciendo que causan pensamientos suicidas en adolescentes. Mi hija ya tiene pensamientos de muerte. ¿Por qué el psiquiatra me receta un medicamento que la FDA dice que causa pensamientos de muerte exactamente en el grupo de Valentina?”

(I need to understand something before giving Valentina this medication. The FDA put a special warning on the box of antidepressants saying they cause suicidal thoughts in teenagers. My daughter already has thoughts of death. Why is the psychiatrist prescribing a medication that the FDA says causes thoughts of death in exactly Valentina’s group?)

Ana recognized the question as the most important one she would answer in this appointment. Ernesto’s concern was not irrational — it was based on a real regulatory action. The gap was not in his information, but in his interpretation of it.

“La pregunta que usted hace es exactamente la correcta, y merece una respuesta completa,” she said. “Porque la advertencia es real, el estudio que la generó es real, y si usted para en el titular ya tiene toda la razón en preocuparse. El problema es que el titular no es la historia completa.”

(The question you are asking is exactly the right one, and it deserves a complete answer. Because the warning is real, the study that generated it is real, and if you stop at the headline you are completely right to be worried. The problem is that the headline is not the complete story.)

She pulled up the FDA medication guide on the clinic tablet.

“En el año 2004, la FDA reanalizó los datos de 24 estudios clínicos de antidepresivos en niños y adolescentes. Lo que encontraron fue un aumento pequeño pero real en los reportes de pensamientos suicidas en los grupos que recibían el medicamento comparado con los grupos que recibían placebo — cuatro por ciento del grupo con medicamento versus dos por ciento del grupo con placebo. Eso es un aumento estadístico real. Y eso es lo que produjo la advertencia.”

(In 2004, the FDA reanalyzed the data from 24 clinical trials of antidepressants in children and adolescents. What they found was a small but real increase in reports of suicidal thoughts in the groups receiving the medication compared to groups receiving placebo — four percent of the medication group versus two percent of the placebo group. That is a real statistical increase. And that is what produced the warning.)

“Eso es lo que leí,” Ernesto said. “Exactamente.” (That is what I read. Exactly.)

“Ahora le digo lo que los titulares normalmente no dicen. Primero: en los cuatro mil cuatrocientos participantes de esos 24 estudios, no hubo ningún suicidio completado. Cero. La advertencia es sobre pensamientos — ideación, en términos médicos — no sobre el suicidio como acto. Segundo: esos pensamientos suicidas que aparecen en las primeras semanas no son nuevos pensamientos insertados por el medicamento en gente que no los tenía. Son pensamientos que ya existían como parte de la depresión — como los que tiene Valentina ahora — que en algunas personas se vuelven más vívidos temporalmente al inicio del tratamiento.”

(Now I will tell you what the headlines usually do not say. First: in the 4,400 participants across those 24 studies, there were no completed suicides. Zero. The warning is about thoughts — ideation, in medical terms — not about suicide as an act. Second: those suicidal thoughts that appear in the first weeks are not new thoughts inserted by the medication into people who did not have them. They are thoughts that already existed as part of the depression — like the ones Valentina has now — that in some people become more vivid temporarily at the start of treatment.)

Ernesto frowned. “¿Por qué?” (Why?)

“Porque el antidepresivo hace dos cosas al principio que no van exactamente a la misma velocidad. Empieza a dar energía — activa los circuitos de la serotonina, reduce la fatiga, puede mejorar algo el sueño — en las primeras semanas. El efecto sobre el estado de ánimo — el levantamiento de la depresión — tarda más, generalmente cuatro a seis semanas. Hay un período entre que la energía sube y que el ánimo sube. En una persona con pensamientos de hacerse daño — como los que tiene Valentina — ese aumento de energía antes del aumento de ánimo puede hacer que esos pensamientos se sientan con más fuerza temporalmente. La persona tiene más energía para actuar sobre los pensamientos que ya tenía antes de que los pensamientos mejoren.”

(Because the antidepressant does two things at the beginning that do not go at exactly the same speed. It starts giving energy — activating serotonin circuits, reducing fatigue, possibly improving sleep somewhat — in the first weeks. The effect on mood — the lifting of the depression — takes longer, typically four to six weeks. There is a period between when the energy rises and when the mood rises. In a person who has thoughts of self-harm — like Valentina has — that increase in energy before the increase in mood can make those thoughts feel stronger temporarily. The person has more energy to act on thoughts they already had before those thoughts improve.)

“¿Entonces el medicamento es peligroso al principio?” (So the medication is dangerous at the beginning?)

“El medicamento tiene un riesgo que es mayor al principio y que por eso tiene un protocolo específico. No es que el medicamento sea inherentemente peligroso — es que el período de titulación requiere vigilancia cercana. Por eso el protocolo es contacto semanal durante las primeras ocho semanas. Le voy a dar una lista de señales específicas: si Valentina está más agitada o más irritable que antes, si habla más de hacerse daño, si usted nota un cambio en su comportamiento. Si ve cualquiera de esas señales, usted me llama ese mismo día. No espera a la cita de la semana que viene.”

(The medication has a risk that is greater at the beginning and that therefore has a specific protocol. It is not that the medication is inherently dangerous — it is that the titration period requires close monitoring. That is why the protocol is weekly contact for the first eight weeks. I am going to give you a list of specific warning signs: if Valentina is more agitated or more irritable than before, if she talks more about hurting herself, if you notice a change in her behavior. If you see any of those signs, you call me that same day. You do not wait for next week's appointment.)

Ernesto was listening carefully. “¿Y la otra parte de la historia? Usted dijo que los titulares no son toda la historia.” (And the other part of the story? You said the headlines are not the whole story.)

“La otra parte es lo que pasa en la población — no en los estudios clínicos, sino en el mundo real. En los años noventa, cuando los antidepresivos como el que le recetamos a Valentina se empezaron a usar masivamente en adolescentes en los Estados Unidos, las tasas de suicidio en adolescentes bajaron de manera significativa y sostenida durante esa década. Después del 2004, cuando la advertencia de la FDA redujo las prescripciones de antidepresivos en adolescentes — exactamente el efecto que usted está considerando en este momento — las tasas de suicidio en adolescentes empezaron a subir. Los datos de la población van en la dirección opuesta al titular.”

(The other part is what happens in the population — not in the clinical trials, but in the real world. In the 1990s, when antidepressants like the one we are prescribing to Valentina started being used extensively in adolescents in the United States, adolescent suicide rates declined significantly and sustainedly over that decade. After 2004, when the FDA warning reduced antidepressant prescriptions in adolescents — exactly the effect you are considering in this moment — adolescent suicide rates started to rise. The population data go in the opposite direction from the headline.)

Ernesto sat with this for a moment. “¿Entonces la advertencia dice una cosa verdadera sobre las primeras semanas, pero la realidad es que el medicamento reduce el suicidio en la población?” (So the warning says something true about the first weeks, but the reality is that the medication reduces suicide in the population?)

“Exactamente. Y la tercera parte de la historia es la comparación justa: comparar el riesgo de darle el medicamento con vigilancia cercana vs. el riesgo de dejar la depresión de Valentina sin tratar. La depresión moderada a severa que tiene Valentina — con nueve criterios, siete semanas, pensamientos pasivos de muerte — tiene un riesgo elevado de intento de suicidio y de recurrencia en la vida adulta si no se trata. No tratar no es una elección sin riesgo. Tratar con el protocolo de vigilancia que le estoy describiendo pone controles específicos sobre el riesgo del período de titulación.”

(Exactly. And the third part of the story is the fair comparison: comparing the risk of giving the medication with close monitoring versus the risk of leaving Valentina’s depression untreated. The moderate-to-severe depression Valentina has — nine criteria, seven weeks, passive thoughts of death — carries an elevated risk of suicide attempt and of recurrence in adult life if left untreated. Not treating is not a risk-free choice. Treating with the monitoring protocol I am describing puts specific controls on the risk of the titration period.)

Ernesto looked at the prescription on the counter. “La advertencia no dice que el medicamento causa suicidio. Dice que las primeras semanas necesitan vigilancia cercana — y por eso Valentina tiene cita cada semana para que usted me llame si algo cambia.” (The warning does not say the medication causes suicide. It says the first weeks need close monitoring — and that is why Valentina has an appointment every week so that you call me if anything changes.)

“Exactamente,” Ana said. “Usted acaba de resumir el protocolo perfectamente. Y si en alguna semana algo cambia y usted llama — esa llamada es exactamente para lo que existe.”

(Exactly. You just summarized the protocol perfectly. And if in any week something changes and you call — that call is exactly what it exists for.)

They spent the next fifteen minutes reviewing the specific warning signs, the dosing schedule, what Valentina should expect in the first two weeks (possibly increased energy before mood improvement, possibly some initial nausea), and when the next appointment would be. Ernesto left with the prescription, the warning signs list, and Ana’s direct line.

Scenario 2: Miguel Santos-Mendoza — 11 years old, San Antonio, Texas

Miguel Santos-Mendoza had been diagnosed with obsessive-compulsive disorder at age ten after his contamination obsessions and washing compulsions had escalated from manageable to consuming. At the time of the clinic visit, Miguel spent between ninety and one hundred fifty minutes per day washing his hands — twenty to thirty washing cycles, each lasting three to five minutes — and refused to touch doorknobs, elevator buttons, shared classroom materials, or any object he had not personally cleaned. He was attending school only on days when his anxiety level was low enough to leave the house, which was three to four days per week. His pediatrician had referred him to the child and adolescent psychiatry clinic, where the child psychiatrist started fluvoxamine at low dose and enrolled Miguel in weekly individual cognitive behavioral therapy with a therapist specializing in pediatric OCD and using exposure and response prevention.

Lucía Mendoza-Santos, a school cafeteria worker, had watched Miguel’s first ERP session through a one-way mirror. The therapist had asked Miguel to touch the doorknob of the clinic bathroom — a task Miguel had been prepared for in the session’s first portion, where they had established a hierarchy of feared objects and the doorknob was near the middle. Miguel had touched the doorknob. The therapist had then explained that the next thirty minutes would be spent sitting with the anxiety without washing. Miguel had sat on the couch with his hands in his lap, visibly distressed, breathing faster than normal, his eyes fixed on the wall. His anxiety was high and visible, and it had not immediately decreased. Lucía had watched this for thirty minutes and then spoken to pediatric psychiatry clinic nurse Elena Herrera-García.

“No entiendo lo que acabo de ver,” she said. “El doctor me explicó que el OCD le produce ansiedad a Miguel y que el tratamiento es para reducir la ansiedad. Lo que yo vi fue que la terapeuta lo hizo tocar algo que lo aterroriza y después no lo dejó lavarse durante media hora. Miguel estaba sufriendo en esa sesión. ¿Cómo es que hacer sufrir a mi hijo más durante media hora es el tratamiento para la ansiedad?”

(I do not understand what I just saw. The doctor explained to me that OCD causes Miguel anxiety and that the treatment is to reduce the anxiety. What I saw was that the therapist made him touch something that terrifies him and then did not let him wash for half an hour. Miguel was suffering in that session. How is making my son suffer more for half an hour the treatment for anxiety?)

Elena recognized the question as the central one in ERP education — the apparent paradox that is the most important thing for a parent to understand before their child can complete therapy.

“Lo que usted vio es exactamente lo que pasa en ERP y es exactamente lo que tiene que pasar,” she said. “La paradoja desaparece cuando entendemos dos cosas: por qué el OCD de Miguel empeora con el tiempo, y por qué la ansiedad que usted vio en esa sesión es el mecanismo que lo va a curar, no el daño que le hace.”

(What you saw is exactly what happens in ERP and is exactly what has to happen. The paradox disappears when we understand two things: why Miguel’s OCD gets worse over time, and why the anxiety you saw in that session is the mechanism that will cure him, not the damage being done to him.)

Elena sat down across from Lucía.

“Para entender por qué el OCD empeora, piense en lo que pasa cuando Miguel lava. Primero: el pensamiento de que tocó algo contaminado le produce ansiedad. Segundo: lavar hace que la ansiedad baje inmediatamente. Tercero: el cerebro de Miguel registra que lavar paró la ansiedad. La próxima vez que toca algo contaminado, el cerebro ya sabe cuál es la solución: lavar. Y la vez siguiente. Y la siguiente. El lavado se vuelve la única herramienta que Miguel tiene para bajar esa ansiedad, porque nunca ha aprendido que la ansiedad puede bajar sola.”

(To understand why OCD gets worse, think about what happens when Miguel washes. First: the thought that he touched something contaminated generates anxiety. Second: washing makes the anxiety drop immediately. Third: Miguel’s brain records that washing stopped the anxiety. The next time he touches something contaminated, the brain already knows the solution: wash. And the next time. And the next. Washing becomes the only tool Miguel has to lower that anxiety, because he has never learned that the anxiety can go down on its own.)

“Eso tiene sentido,” Lucía said. “El lavado lo ayuda.” (That makes sense. Washing helps him.)

“Ayuda en el segundo. Pero hace más daño en el año. Porque cada vez que lava, refuerza la idea de que lavar es necesario. Con el tiempo, el umbral para disparar la ansiedad baja — cosas más pequeñas disparan el ciclo. Los rituales tienen que ser más largos para dar el mismo alivio. El OCD se expande. Hay familias en las que el niño deja de salir de la casa a los trece años porque el mundo exterior parece completamente contaminado. El lavado no resuelve el OCD — lo alimenta.”

(It helps in the second. But it does more damage over the year. Because every time he washes, it reinforces the idea that washing is necessary. Over time, the threshold for triggering the anxiety decreases — smaller things trigger the cycle. The rituals have to be longer to give the same relief. OCD expands. There are families in which the child stops leaving the house at age thirteen because the outside world seems completely contaminated. Washing does not resolve OCD — it feeds it.)

Lucía looked at her hands. “Entonces la terapia tiene que romper ese ciclo.” (So therapy has to break that cycle.)

“Exactamente. Y la única manera de romperlo es que Miguel experimente la ansiedad sin hacer el ritual — y descubra dos cosas que todavía no sabe. Primero: que la ansiedad baja sola, sin lavar, si espera. Segundo: que el desastre que teme — la enfermedad grave de haber tocado la manija — no ocurre. ¿Cómo aprende el cerebro esas dos cosas? Solo con la experiencia. No hay otra forma. La terapeuta no puede decirle a Miguel que la ansiedad va a bajar — Miguel tiene que sentirla bajar. La terapeuta no puede decirle que no se va a enfermar — Miguel tiene que comprobarlo. Por eso la terapia tiene que producir la ansiedad y luego esperar. La ansiedad de la sesión no es un efecto secundario del tratamiento. Es el tratamiento.”

(Exactly. And the only way to break it is for Miguel to experience the anxiety without performing the ritual — and discover two things he does not yet know. First: that the anxiety goes down on its own, without washing, if he waits. Second: that the disaster he fears — serious illness from having touched the doorknob — does not occur. How does the brain learn those two things? Only through experience. There is no other way. The therapist cannot tell Miguel that the anxiety will decrease — Miguel has to feel it decrease. The therapist cannot tell him that he will not get sick — Miguel has to verify it. That is why the therapy has to produce the anxiety and then wait. The anxiety in the session is not a side effect of the treatment. It is the treatment.)

Lucía looked at the one-way mirror window. “¿Y al final de la sesión — cómo estaba Miguel?” (And at the end of the session — how was Miguel?)

“Cuando la terapeuta le preguntó al final de los treinta minutos qué tan alta estaba su ansiedad en una escala del uno al diez, Miguel dijo cuatro. Al principio dijo ocho. Sin lavar. Eso es la habituación — la respuesta biológica del cerebro en la que la señal de alarma baja cuando la amenaza no se materializa. Lo que Miguel aprendió en esa sesión es que tocó la manija y la ansiedad bajó sola, de ocho a cuatro, en treinta minutos. Y que no se enfermó. Con cada sesión así, la conexión entre “toqué algo” y “tengo que lavarme” se hace más débil. No de golpe — gradualmente. Pero se hace más débil.”

(When the therapist asked at the end of the thirty minutes how high his anxiety was on a scale of one to ten, Miguel said four. At the beginning he had said eight. Without washing. That is habituation — the biological brain response in which the alarm signal decreases when the threat does not materialize. What Miguel learned in that session is that he touched the doorknob and the anxiety came down on its own, from eight to four, in thirty minutes. And that he did not get sick. With each session like that, the connection between “I touched something” and “I have to wash” becomes weaker. Not all at once — gradually. But it becomes weaker.)

Lucía was quiet for a long moment. “Entonces lo que yo vi como sufrimiento — que Miguel estaba sufriendo — era real. Pero estaba sufriendo de una manera útil.” (So what I saw as suffering — that Miguel was suffering — was real. But he was suffering in a useful way.)

“Estaba aprendiendo,” Elena said. “El sufrimiento era real. El aprendizaje era real también. Son la misma cosa en la ERP. Lo que usted tiene que monitorear en casa no es el nivel de ansiedad de Miguel en la exposición — ese va a ser alto y tiene que ser alto. Lo que usted tiene que monitorear es que no permite rituales durante el tiempo acordado con la terapeuta. Si usted le dice a Miguel “ya, lávate” cuando lo ve angustiado, la sesión empieza de nuevo desde cero. Usted es parte del tratamiento.”

(He was learning. The suffering was real. The learning was real too. They are the same thing in ERP. What you have to monitor at home is not Miguel’s anxiety level during the exposure — that is going to be high and has to be high. What you have to monitor is that you do not allow rituals during the time agreed with the therapist. If you say to Miguel “okay, go wash” when you see him distressed, the session starts again from zero. You are part of the treatment.)

Lucía absorbed this. “La terapia no es para que no sienta la ansiedad. Es para que aprenda que puede aguantarla sin lavar, y que lavarse no es la única manera de sobrevivir al miedo.” (The therapy is not so that he does not feel the anxiety. It is so that he learns that he can endure it without washing, and that washing is not the only way to survive the fear.)

“Eso es exactamente lo que la terapia está haciendo,” Elena said.

Scenario 3: Andrés Reyes-Castellanos — 17 years old, Dallas, Texas

Andrés Reyes-Castellanos had been brought to the pediatric psychiatric emergency room by his mother and his girlfriend after four weeks of progressive changes that his girlfriend described as “he became someone else.” He had begun hearing voices commenting on his actions — not hostile initially, but persistent; later occasional commands to perform actions that frightened him. He had developed a conviction that his neighbors were using his phone to surveil him and report his movements to an unnamed third party. His speech had become intermittently tangential. He had stopped attending school three weeks earlier and spent most of his time in his room with the blinds down.

The psychiatric evaluation confirmed a first episode psychosis. Andrés had used cannabis heavily — daily for the preceding two months, with a significant increase in frequency and potency in the six weeks before symptom onset — and his girlfriend noted that the personality changes began approximately four weeks into the heavier use period. Andrés had voluntarily stopped cannabis three days before the emergency visit when his mother found him in the kitchen at 3 AM talking to someone who was not there. The emergency psychiatrist prescribed risperidone 1 mg daily titrating to 2 mg over four weeks and arranged outpatient follow-up at the pediatric psychiatry clinic.

Elena Castellanos-Ortiz, Andrés’s mother and a dental receptionist, had been researching cannabis and psychosis since the emergency visit. She had found information about “cannabis psychosis” and had concluded that since Andrés had stopped cannabis three days ago, the psychosis should already be improving, and that the persistent symptoms meant either the psychosis needed more time to clear or the diagnosis was wrong. She could not understand why risperidone — which she had read could cause significant weight gain, metabolic syndrome, and sedation, with long-term effects she worried about — was being prescribed for something that should resolve on its own now that the cannabis had stopped.

“El psiquiatra me dijo que la marihuana desencadenó la psicosis de Andrés,” she said to pediatric psychiatry clinic nurse Rosa Villanueva-Torres. “Andrés lleva tres días sin marihuana. Si la marihuana la causó, ¿por qué los síntomas no mejoran? ¿Y por qué le recetan un medicamento que causa aumento de peso y sedación cuando si esperamos unos días más tal vez se resuelve solo?”

(The psychiatrist told me that marijuana triggered Andrés’s psychosis. Andrés has been without marijuana for three days. If the marijuana caused it, why are the symptoms not improving? And why are they prescribing a medication that causes weight gain and sedation when if we wait a few more days maybe it resolves on its own?)

Rosa recognized this as the question she needed to answer carefully — the causal model Elena had was accurate for one type of cannabis-associated psychosis and wrong for another, and distinguishing them was the clinical key.

“La pregunta que usted hace es exactamente la que distingue dos situaciones diferentes que se llaman de manera parecida pero son biológicamente distintas,” she said. “Una se llama psicosis por intoxicación de cannabis. La otra se llama primer episodio psicótico precipitado por cannabis. Lo que Andrés tiene es la segunda, y entender la diferencia explica por qué los tres días sin marihuana no la han resuelto.”

(The question you are asking is exactly the one that distinguishes two different situations that are named similarly but are biologically distinct. One is called cannabis intoxication psychosis. The other is called cannabis-precipitated first episode psychosis. What Andrés has is the second, and understanding the difference explains why the three days without marijuana have not resolved it.)

“Explíqueme la diferencia,” Elena said.

(Explain the difference to me.)

“La psicosis por intoxicación ocurre cuando el THC — el componente activo de la marihuana — está presente en el cerebro a concentraciones altas. El THC activa unos receptores en el cerebro que distorsionan la percepción y el pensamiento. Cuando el cuerpo elimina el THC — lo que tarda horas, máximo un día — esa distorsión desaparece. Si Andrés tuviera ese tipo de psicosis, habría desaparecido el primer día que paró. No el segundo. No el tercero. El primero. Andrés lleva tres días sin marihuana y las alucinaciones y los miedos siguen ahí. Eso es la evidencia clínica de que lo que tiene no depende de que la marihuana esté presente en su cuerpo ahora mismo.”

(Intoxication psychosis occurs when THC — the active component of marijuana — is present in the brain at high concentrations. THC activates receptors in the brain that distort perception and thought. When the body eliminates the THC — which takes hours, at most a day — that distortion disappears. If Andrés had that type of psychosis, it would have disappeared the first day he stopped. Not the second. Not the third. The first. Andrés has been without marijuana for three days and the hallucinations and fears are still there. That is the clinical evidence that what he has does not depend on marijuana being present in his body right now.)

Elena was looking at Rosa carefully. “¿Entonces qué tipo de psicosis tiene Andrés?” (So what type of psychosis does Andrés have?)

“Lo que tiene se llama primer episodio psicótico precipitado por cannabis. ‘Precipitado’ significa que la marihuana lo desencadenó — fue el detonador — pero no es lo que lo está causando ahora mismo. Para entender por qué, tengo que explicarle algo sobre cómo el cerebro de los adolescentes se desarrolla, y por qué la marihuana es especialmente peligrosa en ese período.”

(What he has is called cannabis-precipitated first episode psychosis. ‘Precipitated’ means that marijuana triggered it — it was the trigger — but it is not what is causing it right now. To understand why, I need to explain something about how adolescent brains develop, and why marijuana is especially dangerous during that period.)

“Adelante,” Elena said. (Go ahead.)

“El cerebro de Andrés — tiene diecisiete años — está en el medio de un proceso de maduración que va a terminar aproximadamente a los veinticinco. Durante ese proceso, el cerebro está refinando activamente las conexiones entre diferentes regiones — especialmente entre la corteza prefrontal, que es donde tomamos decisiones y controlamos impulsos, y las regiones más profundas del cerebro que producen dopamina. Ese refinamiento se llama poda sináptica, y es esencial para que el cerebro maduro funcione de manera eficiente. Ahora: la marihuana interfiere con ese proceso de una manera específica. El THC actúa sobre los mismos receptores que las señales endocannabinoides naturales del cerebro que guían la poda sináptica. Cuando hay THC en el cerebro con frecuencia durante la adolescencia, interfiere con esas señales, y la poda sináptica se altera.”

(Andrés’s brain — he is seventeen — is in the middle of a maturation process that will finish at approximately age twenty-five. During that process, the brain is actively refining the connections between different regions — especially between the prefrontal cortex, where we make decisions and control impulses, and the deeper brain regions that produce dopamine. This refinement is called synaptic pruning, and it is essential for the mature brain to function efficiently. Now: marijuana interferes with this process in a specific way. THC acts on the same receptors as the brain’s natural endocannabinoid signals that guide synaptic pruning. When THC is in the brain frequently during adolescence, it interferes with those signals, and synaptic pruning is disrupted.)

“¿Y eso produce psicosis en todos los adolescentes que usan marihuana?” Elena asked. (And that produces psychosis in all adolescents who use marijuana?)

“No. En la mayoría no. Lo produce en adolescentes que tienen una vulnerabilidad genética para los trastornos del espectro psicótico — una vulnerabilidad que está presente en aproximadamente el uno al tres por ciento de la población. En esos individuos, el THC altera un sistema que ya estaba en riesgo de desregularse. El efecto es que la dopamina en el sistema mesolímbico — la parte del cerebro conectada con las percepciones y las emociones — se produce y libera en cantidades excesivas, y los receptores de dopamina se vuelven más sensibles de lo normal. Esa desregulación de la dopamina es el mecanismo que produce las alucinaciones y los delirios — las voces que escucha Andrés, el miedo de que los vecinos lo vigilan. Una vez que esa desregulación se inicia en un adolescente vulnerable, adquiere un mecanismo neurobiológico propio que funciona de manera independiente de si hay THC en el cuerpo o no.”

(No. Not in the majority. It produces it in adolescents who have a genetic vulnerability for psychotic spectrum disorders — a vulnerability present in approximately one to three percent of the population. In those individuals, THC alters a system that was already at risk of dysregulation. The effect is that dopamine in the mesolimbic system — the part of the brain connected to perceptions and emotions — is produced and released in excessive amounts, and the dopamine receptors become more sensitive than normal. That dopamine dysregulation is the mechanism that produces the hallucinations and delusions — the voices Andrés hears, the fear that neighbors are surveilling him. Once that dysregulation begins in a vulnerable adolescent, it acquires its own neurobiological mechanism that functions independently of whether THC is in the body or not.)

Elena was quiet. “¿Cómo saben que Andrés tiene esa vulnerabilidad?” (How do you know Andrés has that vulnerability?)

“La vulnerabilidad no siempre es visible antes de que el primer episodio ocurra. Lo que nos dice que Andrés la tenía es que la psicosis ocurrió. En alguien sin esa vulnerabilidad genética, el mismo nivel de uso de marihuana habría producido intoxicación — que se resuelve en horas — no un primer episodio psicótico que persiste semanas. Los estudios de seguimiento de personas con psicosis precipitada por cannabis muestran que entre el treinta y cinco y el cincuenta por ciento desarrollan un trastorno psicótico persistente — esquizofrenia o trastorno esquizoafectivo — incluso con abstinencia completa y verificada de cannabis. Eso confirma que el trastorno adquirió un mecanismo propio independiente de la droga.”

(The vulnerability is not always visible before the first episode occurs. What tells us Andrés had it is that the psychosis occurred. In someone without that genetic vulnerability, the same level of cannabis use would have produced intoxication — which resolves in hours — not a first episode psychosis that persists weeks. Follow-up studies of people with cannabis-precipitated psychosis show that between thirty-five and fifty percent develop a persistent psychotic disorder — schizophrenia or schizoaffective disorder — even with complete and verified cannabis abstinence. That confirms that the disorder acquired its own mechanism independent of the drug.)

Elena’s expression was frightened. “¿Entonces Andrés va a tener esquizofrenia?” (So Andrés is going to have schizophrenia?)

“No lo sabemos todavía. Lo que sí sabemos es que el tratamiento temprano cambia la probabilidad. Los estudios muestran que el tratamiento antipsicótico rápido en el primer episodio — en las primeras semanas — está asociado con mejores resultados funcionales a dos y cinco años que el tratamiento tardío o ningún tratamiento. Cuanto más tiempo está la psicosis sin tratar, más tiempo la desregulación de la dopamina está activa, y más daño hace a los circuitos que están todavía en maduración en el cerebro de Andrés. Empezar el tratamiento ahora es exactamente lo correcto para reducir el riesgo de que esto se vuelva algo crónico.”

(We do not know yet. What we do know is that early treatment changes the probability. Studies show that rapid antipsychotic treatment in first episode — in the first weeks — is associated with better functional outcomes at two and five years than delayed or no treatment. The longer the psychosis goes untreated, the longer the dopamine dysregulation is active, and the more damage it does to the circuits that are still maturing in Andrés’s brain. Starting treatment now is exactly the right thing to reduce the risk of this becoming something chronic.)

“¿Y el risperidona — cómo funciona?” (And the risperidone — how does it work?)

“La risperidona bloquea los receptores de dopamina D2 en el sistema mesolímbico — los mismos receptores que están hipersensibles y produciendo las voces y los miedos. Al bloquear esos receptores, normaliza la actividad de la dopamina en esas regiones. Eso es el mecanismo que reduce las alucinaciones y los delirios. No es una sedación — es una normalización de la química.”

(Risperidone blocks D2 dopamine receptors in the mesolimbic system — the same receptors that are hypersensitive and producing the voices and the fears. By blocking those receptors, it normalizes dopamine activity in those regions. That is the mechanism that reduces the hallucinations and delusions. It is not sedation — it is a normalization of the chemistry.)

“¿Y el aumento de peso?” (And the weight gain?)

“Real y lo vigilamos. La risperidona tiene efectos sobre los receptores del hambre que pueden producir aumento de apetito y de peso. Hacemos un panel metabólico — glucosa, colesterol, triglicéridos — al inicio, a los tres meses, y cada seis meses. Si el aumento de peso es significativo, tenemos opciones — ajuste de dosis, cambio a otro antipsicótico con menos efecto metabólico, o metformina si es necesario. Los efectos secundarios son manejables y reversibles. Los síntomas psicóticos sin tratamiento no son ninguna de esas cosas.”

(Real and we monitor it. Risperidone has effects on hunger receptors that can produce increased appetite and weight. We do a metabolic panel — glucose, cholesterol, triglycerides — at baseline, at three months, and every six months. If weight gain is significant, we have options — dose adjustment, switch to another antipsychotic with less metabolic effect, or metformin if necessary. The side effects are manageable and reversible. Psychotic symptoms without treatment are neither of those things.)

Elena looked at the prescription she had been carrying since the emergency visit three days ago. “Si la marihuana estuviera causando los síntomas ahora mismo — como una intoxicación — habrían desaparecido el primer día que paró. Llevan cuatro semanas y tres días sin marihuana. La marihuana encendió algo que ahora funciona solo.” (If the marijuana were causing the symptoms right now — like an intoxication — they would have disappeared the first day he stopped. It has been four weeks and three days without marijuana. The marijuana lit something that now works on its own.)

“Exactamente,” Rosa said. “Y el antipsicótico normaliza lo que se encendió. La abstinencia de la marihuana es necesaria — seguir usando haría el tratamiento imposible y aumentaría el riesgo de empeoramiento. Pero la abstinencia sola no es suficiente para lo que Andrés tiene ahora.”

(Exactly. And the antipsychotic normalizes what was lit. Abstinence from marijuana is necessary — continued use would make treatment impossible and would increase the risk of worsening. But abstinence alone is not sufficient for what Andrés has now.)

They spent the next twenty minutes reviewing the monitoring plan, the specific signs of worsening that would warrant an emergency call, what risperidone side effects were expected versus which warranted contact, and what Andrés could realistically expect in the first four to six weeks of treatment. Elena left with the prescription, the monitoring schedule, and a sentence she would use to explain the situation to Andrés’s father, who had not been at the emergency visit: La marihuana encendió algo en el cerebro de Andrés que ahora funciona por su cuenta. El medicamento apaga eso. La abstinencia es necesaria pero no es suficiente. (The marijuana lit something in Andrés’s brain that now works on its own. The medication turns that off. Abstinence is necessary but not sufficient.)

What these three conversations have in common

Ernesto with his model built from a true regulatory fact drawn to an incorrect clinical conclusion, Lucía with her direct visual evidence of her son’s distress interpreted as therapeutic error, Elena with her causal model of cannabis-causes-psychosis that was accurate for one diagnosis and wrong for another — each arrived at the pediatric psychiatry clinic with a coherent model that was specifically incomplete in a way that made the recommended treatment seem irrational, harmful, or unnecessary. These were not failures of intelligence or attention. They were failures of information: the black box warning does not include the epidemiological context; watching an ERP session does not reveal the habituation mechanism; knowing that cannabis triggered the psychosis does not automatically convey the distinction between precipitation and intoxication.

The nurse’s work in each case was the same: identify exactly which piece of the model was missing, build that piece, and connect it to the treatment instruction in a way the parent could verify and repeat. Ernesto needed the distinction between suicidal ideation and completed suicide, the activation syndrome mechanism, and the comparative risk of untreated depression before the monitoring protocol made sense as protective rather than insufficient. Lucía needed the operant conditioning of the compulsion cycle and the habituation mechanism before Miguel’s distress looked like progress rather than damage. Elena needed the intoxication/precipitation distinction and the dopamine dysregulation timeline before the antipsychotic made sense as a treatment rather than an overreach.

For pediatric psychiatry clinic nurses working with Spanish-speaking families, the specific challenge of this specialty is that its treatments are among the most counterintuitive in medicine: you give a medication that the government warns increases suicidal thoughts to a teenager who has suicidal thoughts; you deliberately make an anxious child more anxious as a treatment for anxiety; you prescribe a medication with metabolic side effects for a condition the parent believes will resolve on its own. In each case, the counter-intuition dissolves when the mechanism is understood. And in Spanish, to a family that may have limited prior contact with mental health care and strong cultural frameworks about what mental illness means, building that mechanism from first principles in a fifteen-minute clinic encounter is the nurse’s core competency.

Clinical Spanish reference: pediatric psychiatry

SSRI treatment for adolescent depression

Trastorno depresivo mayor — major depressive disorder: La depresión mayor no es solo tristeza — es un trastorno neurobiológico con nueve criterios diagnósticos que incluyen síntomas físicos como insomnio y fatiga, no solo emocionales.
Ideación suicida pasiva — passive suicidal ideation: La ideación pasiva son pensamientos de muerte o de desear estar muerto sin un plan activo. Es parte de la depresión, no una emergencia inmediata, pero requiere vigilancia y tratamiento.
Advertencia de la FDA / caja negra — FDA black box warning: La advertencia habla de un aumento temporal en los pensamientos suicidas en las primeras semanas de tratamiento, no en el suicidio completado. El protocolo de vigilancia semanal es la respuesta clínica a esa advertencia.
Síndrome de activación — activation syndrome: En las primeras semanas, el ISRS puede aumentar la energía antes de que mejore el estado de ánimo. En un paciente con ideación pasiva, ese período requiere vigilancia específica: más agitación, más impulsividad, aumento en los pensamientos de hacerse daño.
Inhibidor selectivo de la recaptación de serotonina (ISRS) — SSRI: El ISRS aumenta la disponibilidad de serotonina en el cerebro. El efecto completo sobre el estado de ánimo tarda cuatro a seis semanas. El aumento de energía puede empezar antes.

OCD and exposure and response prevention

Trastorno obsesivo-compulsivo (TOC) — obsessive-compulsive disorder: El TOC consiste en obsesiones — pensamientos intrusivos que producen ansiedad — y compulsiones — rituales que reducen esa ansiedad temporalmente pero la refuerzan a largo plazo.
Exposición y prevención de respuesta (EPR / ERP) — exposure and response prevention: La EPR expone al paciente al estímulo temido y le impide realizar el ritual. La ansiedad sube y luego baja sola por habituación. Cada exposición exitosa debilita la conexión entre el estímulo y la ansiedad.
Habituación — habituation: La habituación es la respuesta biológica del cerebro por la que la señal de alarma disminuye cuando la amenaza temida no se materializa. Es el mecanismo terapéutico de la ERP.
Ciclo de ansiedad-ritual-alivio — anxiety-compulsion-relief cycle: El OCD se mantiene porque el ritual da alivio inmediato, reforzando la compulsión. La ERP interrumpe ese ciclo al mostrarle al cerebro que el alivio puede ocurrir sin el ritual.
Jerarquía de exposición — exposure hierarchy: La jerarquía ordena los estímulos temidos de menos a más aterradores. La terapia empieza por los más bajos y progresa gradualmente. Esto no es para proteger al paciente de la ansiedad — es para calibrar la dosis de exposición.

First episode psychosis and antipsychotics

Primer episodio psicótico — first episode psychosis: El primer episodio psicótico incluye alucinaciones, delirios, pensamiento desorganizado y/o cambios de personalidad significativos. El tratamiento rápido mejora los resultados a largo plazo.
Psicosis precipitada por cannabis — cannabis-precipitated psychosis: La marihuana puede desencadenar un primer episodio psicótico en adolescentes con vulnerabilidad genética. A diferencia de la intoxicación, que se resuelve en horas, la psicosis precipitada persiste después de la abstinencia porque adquiere un mecanismo neurobiológico independiente.
Desregulación de la dopamina — dopamine dysregulation: La psicosis psicótica positiva — alucinaciones y delirios — está producida por exceso de actividad dopaminérgica en el sistema mesolímbico. Los antipsicóticos normalizan esa actividad bloqueando receptores D2.
Antipsicótico / risperidona — antipsychotic / risperidone: La risperidona bloquea los receptores de dopamina D2 en el sistema mesolímbico reduciendo las alucinaciones y los delirios. Los efectos metabólicos — aumento de peso, glucosa — se vigilan con análisis cada tres meses.
Poda sináptica adolescente — adolescent synaptic pruning: El cerebro adolescente está en un proceso de refinamiento de circuitos hasta los veinticinco años. El THC interfiere con ese proceso en individuos con vulnerabilidad genética, desregulando los circuitos de dopamina que están todavía madurando.

Spanish for psychiatric nurses — adult psychiatric nursing conversations: acute agitation, capacity assessment, involuntary hold
Spanish for pediatric developmental and behavioral clinic nurses — autism spectrum disorder, ADHD stimulant treatment, Down syndrome behavioral changes
Spanish for pediatric neurology clinic nurses — seizure management, antiepileptic medications, and neurological conversations in Spanish
Spanish for pediatric nurses — foundational clinical Spanish for inpatient pediatric settings
Spanish for pediatric neuro-oncology late effects clinic nurses — craniopharyngioma, hypothalamic obesity, and late effects conversations

ClinicaLingo builds clinical-Spanish fluency through scenario-based practice, voiced by AI patients across the real encounters working US nurses face. Join the waitlist for early access, or download the free 50 Spanish ED phrases PDF. Browse all clinical-Spanish posts or practice a scenario.